Healthcare Industry News: adalimumab)
News Release - February 13, 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Source: Eli Lilly
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
Related News Items
Lilly to Acquire AtaiBeckley to Advance Therapies for Treatment-Resistant Depression and Other Mental Health ConditionsLilly to Acquire Ajax Therapeutics to Advance Outcomes for Patients with Myelofibrosis and Polycythemia Vera
Lilly's Jaypirca (Pirtobrutinib) Significantly Extended Progression-Free Survival When Added to a Venetoclax Time-Limited Regimen in Patients with Previously Treated CLL/SLL
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!